ArticleAntimicrobial agents and chemotherapy2003
Is it time to change fluoroquinolone breakpoints for Salmonella spp.?
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Trial
- The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy.PLoS neglected tropical diseases · 2011Trial
- Trial
- Antimicrobial resistance in non-typhoidal salmonellas from humans in Northern Ireland, 2001-2003: standardization needed for better epidemiological monitoring.Epidemiology and infection · 2007Trial
- Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.Antimicrobial agents and chemotherapy · 2007Trial
- Genomic Diversity, Antimicrobial Resistance, Plasmidome, and Virulence Profiles ofAntibiotics (Basel, Switzerland) · 2023Article
- The Diversity ofMicroorganisms · 2023Review
- Article
- Dissemination of antimicrobial-resistant isolates of Salmonella spp. in wild boars and its relationship with management practices.Transboundary and emerging diseases · 2022Article
- Tissue compartmentalization enablesProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Novel chromosomal insertions of ISEcp1-blaAntimicrobial resistance and infection control · 2021Article
- [Active surveillance of nontyphoidal Salmonella enterica strains with nonclassical quinolone resistance phenotype (2014-2019)].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Article
- Overexpression of RamA, Which Regulates Production of the Multidrug Resistance Efflux Pump AcrAB-TolC, Increases Mutation Rate and Influences Drug Resistance Phenotype.Antimicrobial agents and chemotherapy · 2020Article
- Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.Journal of clinical microbiology · 2019Review
- Plasmid-mediated quinolone resistance in human non-typhoidal Salmonella infections: An emerging public health problem in the United States.Zoonoses and public health · 2018Article
- Antimicrobial use by WHO methodology at primary health care centers: a cross sectional study in Punjab, Pakistan.BMC infectious diseases · 2018Article
- The Global Regulatory Cyclic AMP Receptor Protein (CRP) Controls Multifactorial Fluoroquinolone Susceptibility in Salmonella enterica Serovar Typhimurium.Antimicrobial agents and chemotherapy · 2017Article
- Resistance mechanisms and fitness of Salmonella Typhimurium and Salmonella Enteritidis mutants evolved under selection with ciprofloxacin in vitro.Scientific reports · 2017Article
- Comparative study of all Salmonella enterica serovar Enteritidis strains isolated from food and food animals in Greece from 2008 to 2010 with clinical isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Article
- A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.